Clinical Trial: Letermovir Prophylaxis for CMV Infection in Haplo-HSCT Recipients: Single-center Data in China
Study Status: COMPLETED
Recruit Status: COMPLETED
Condition: CMV Infection
Study Type: OBSERVATIONAL
Official Title: Letermovir Prophylaxis for Cytomegalovirus Infection in Haploidentical Allogeneic Hematopoietic Cell Transplant Recipients: Single-center Real-world Data in China
Brief Summary:
In the 30 years of fighting CMV infection, the mortality rate among HSCT patients has significantly reduced.Now, the focus is on improving the prognosis of HSCT patients and preventing CMV infection.The emergence of letermovir has provided a new opportunity in this regard.Letermovir, the only drug approved for CMV infection prevention in HSCT patients, works by inhibiting the CMV DNA terminase complex.Phase III studies have shown that letermovir significantly reduces CMV infection and all-cause mortality after…
Read more